|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators.
|
22850568 |
2012 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4) appears to be a useful biomarker to identify melanoma cells and an attractive target to apply antibody-based immunotherapy for the treatment of melanoma.
|
24258997 |
2014 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HOM-MEL-40 antigen which is encoded by the SSX-2 gene was originally detected as a tumor antigen recognized by autologous IgG antibodies in a melanoma patient.
|
9639388 |
1998 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The human tyrosinase-derived peptide YMDGTMSQV is presented on the surface of human histocompatibility leukocyte antigen (HLA)-A*0201(+) melanomas and has been suggested to be a tumor antigen despite the fact that tyrosinase is also expressed in melanocytes.
|
10748239 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MART-1/Melan-A human melanoma tumor antigen can be recognized by T lymphocytes and appears to be involved in tumor regression.
|
9218710 |
1997 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
The properties of the TAG antigens indicate that they are excellent vaccine candidates for the treatment of melanoma and perhaps other cancers.
|
14871852 |
2004 |
|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results indicated that EGF G1380A and bFGF C754G gene polymorphisms were associated with the susceptibility and prognosis of malignant melanoma, and that the polymorphisms of EGF G1380A and bFGF C754G as well as the haploid TAG increased the susceptibility of malignant melanoma.
|
28219779 |
2017 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, TAP expression restores both antigen presentation and immunogenicity in A375 melanoma cells and concomitantly increases IL-12 and IFN-gamma production in tumor antigen-specific CTLs; TAP should be considered as a part of the immunotherapies for MM.
|
18385764 |
2008 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that TAG-derived peptides may be good components of a therapeutic vaccine designed to target melanoma and a variety of epithelial cell-derived malignancies.
|
18157007 |
2008 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that the efficacy of melanoma DC-based immunotherapy is enhanced when tumor antigen-loaded DCs used for vaccination express cPs.
|
23934126 |
2013 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, a unique tumor antigen can be as immunogenic as the melanoma differentiation antigens but, in contrast to the latter, may be retained in all metastatic cells possibly as result of the relevant cellular function exerted by the mutated protein.
|
15695408 |
2005 |
|
LINC01194
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate this, we determined the specificity of T cells from melanoma patients treated with DCs loaded with mRNA encoding a full-length tumor antigen fused to a signal peptide and an HLA class II sorting signal, allowing presentation in HLA class I and II.
|
22371843 |
2012 |
|
LINC01194
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TriMix DCs coelectroporated with whole tumor-antigen mRNA stimulate antigen-specific T cells in vitro and induce antigen-specific T-cell responses in melanoma patients through vaccination.
|
19417017 |
2009 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using several different preexisting tumor models that make use of B16F10 melanoma cells expressing a target tumor antigen (human melanoma-associated gene [MAGE]-1), we found that vaccination with bone marrow-derived DCs engineered to express MAGE-1 via adenoviral-mediated gene transfer led to a dramatic decrease in the number of metastases in a lung metastasis model, and led to prolonged survival and some long-term cures in a subcutaneous preexisting tumor model.
|
10811863 |
2000 |
|
LINC01194
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously reported the presence of OX-40(+) T cells in head and neck cancer and melanoma, where they appear to be restricted to tumor compartments (primary tumor infiltrating lymphocytes [TILs] and draining lymph node cells) and therefore may represent the tumor antigen-specific CD4(+) T cells.
|
10930490 |
2000 |
|
LINC01194
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes.
|
15386406 |
2005 |